Mapatumumab (HGS-ETR1) is an experimental human monoclonal antibody undergoing clinical trials for the treatment of cancer. It targets TRAIL-R1, also...
9 KB (751 words) - 21:40, 20 December 2023
Denosumab Drozitumab Enavatuzumab Iratumumab Lexatumumab Lucatumumab Mapatumumab Oxelumab Ruplizumab Tabalumab Tavolixizumab Teneliximab Tigatuzumab Toralizumab...
52 KB (6,302 words) - 07:19, 27 April 2024
targets of several anti-cancer therapeutics since the mid-1990s, such as Mapatumumab. However, as of 2013, these have not shown significant survival benefit...
11 KB (1,335 words) - 11:31, 25 August 2023
develop antibody therapeutics. This deal generated belimumab, raxibacumab, mapatumumab and lexatumumab. In April 2012, the first three of these products formed...
11 KB (1,079 words) - 08:48, 3 November 2023
Atoltivimab/maftivimab/odesivimab for treatment of Zaire ebolavirus (Ebola virus) Mapatumumab mab human TRAIL-R1 cancer Margetuximab Margenza mab humanized HER2 Y...
135 KB (4,054 words) - 22:35, 2 July 2024
hexanitrate (INN) mannomustine (INN) mannosulfan (INN) manozodil (INN) Maolate mapatumumab (INN) mapinastine (INN) mapracorat (INN) maprotiline (INN) maraciclatide...
4 KB (272 words) - 02:01, 1 July 2024
Denosumab Drozitumab Enavatuzumab Iratumumab Lexatumumab Lucatumumab Mapatumumab Oxelumab Ruplizumab Tabalumab Tavolixizumab Teneliximab Tigatuzumab Toralizumab...
8 KB (501 words) - 01:30, 27 December 2023
Denosumab Drozitumab Enavatuzumab Iratumumab Lexatumumab Lucatumumab Mapatumumab Oxelumab Ruplizumab Tabalumab Tavolixizumab Teneliximab Tigatuzumab Toralizumab...
8 KB (316 words) - 22:44, 25 April 2024
Denosumab Drozitumab Enavatuzumab Iratumumab Lexatumumab Lucatumumab Mapatumumab Oxelumab Ruplizumab Tabalumab Tavolixizumab Teneliximab Tigatuzumab Toralizumab...
19 KB (2,200 words) - 05:21, 25 December 2023
Denosumab Drozitumab Enavatuzumab Iratumumab Lexatumumab Lucatumumab Mapatumumab Oxelumab Ruplizumab Tabalumab Tavolixizumab Teneliximab Tigatuzumab Toralizumab...
24 KB (2,853 words) - 21:22, 2 April 2024
Denosumab Drozitumab Enavatuzumab Iratumumab Lexatumumab Lucatumumab Mapatumumab Oxelumab Ruplizumab Tabalumab Tavolixizumab Teneliximab Tigatuzumab Toralizumab...
12 KB (1,356 words) - 18:10, 27 December 2023
Denosumab Drozitumab Enavatuzumab Iratumumab Lexatumumab Lucatumumab Mapatumumab Oxelumab Ruplizumab Tabalumab Tavolixizumab Teneliximab Tigatuzumab Toralizumab...
12 KB (1,494 words) - 10:51, 13 August 2023
Ipilimumab Iratumumab§ Istiratumab Icrucumab§ Lexatumumab§ Lucatumumab§ Mapatumumab§ Narnatumab§ Necitumumab Nesvacumab§ Nivolumab# Ofatumumab Olaratumab†...
4 KB (241 words) - 11:41, 22 April 2022
Denosumab Drozitumab Enavatuzumab Iratumumab Lexatumumab Lucatumumab Mapatumumab Oxelumab Ruplizumab Tabalumab Tavolixizumab Teneliximab Tigatuzumab Toralizumab...
12 KB (1,508 words) - 17:56, 19 August 2022
Denosumab Drozitumab Enavatuzumab Iratumumab Lexatumumab Lucatumumab Mapatumumab Oxelumab Ruplizumab Tabalumab Tavolixizumab Teneliximab Tigatuzumab Toralizumab...
12 KB (1,459 words) - 03:14, 30 October 2022
Ipilimumab Iratumumab§ Istiratumab Icrucumab§ Lexatumumab§ Lucatumumab§ Mapatumumab§ Narnatumab§ Necitumumab Nesvacumab§ Nivolumab# Ofatumumab Olaratumab†...
3 KB (129 words) - 01:04, 19 July 2023
Ipilimumab Iratumumab§ Istiratumab Icrucumab§ Lexatumumab§ Lucatumumab§ Mapatumumab§ Narnatumab§ Necitumumab Nesvacumab§ Nivolumab# Ofatumumab Olaratumab†...
5 KB (368 words) - 22:00, 19 October 2020
risk-benefit profile of raxibacumab". Two anti-TRAIL receptor antibodies – mapatumumab (HGS-ETR1) and lexatumumab (HGS-ETR2). Early work by CAT and HGS scientists...
91 KB (8,495 words) - 02:27, 30 December 2023